Psychopharmacologic validation of atypical depression.
Sixty patients meeting specific criteria for atypical depression completed 6 weeks of double-blind, randomly assigned treatment with phenelzine, imipramine, or placebo. Patients who had a history of spontaneous panic attacks or hysteriod dysphoric features showed extremely low placebo-response rates, moderate responses to imipramine, and high rates of response to phenelzine. Conversely, patients without such features responded moderately well to all three treatments. Based on preliminary data, MAOI-specific atypical depression does appear to exist, although in more delimited forms than previously recognized.
D000293:Adolescent; D000328:Adult; D001008:Anxiety Disorders / Q000175:diagnosis; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010200:Panic; D010624:Phenelzine / Q000627:therapeutic use*; D010919:Placebos; D011897:Random Allocation
D010919:Placebos; D010624:Phenelzine; D007099:Imipramine